Biocon · NSE: BIOCON · BSE: 532523
Q4 FY25 results · Jan–Mar 2025
Biocon reported revenue from operations of ₹4,417.00 crore (up 12.8% from Q4 FY24) and net profit of ₹459.40 crore (up 106.1% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,417.00 | 3,917.10 | +12.8% | 3,821.40 | +15.6% |
| Other income | 36.90 | 48.60 | −24.1% | 34.80 | +6.0% |
| Total income | 4,453.90 | 3,965.70 | +12.3% | 3,856.20 | +15.5% |
| Profit before tax | 486.80 | 321.70 | +51.3% | 155.90 | +212.3% |
| Net profit for the period | 459.40 | 222.90 | +106.1% | 81.10 | +466.5% |
| Attributable to shareholders of the company | 344.50 | 135.50 | +154.2% | 25.10 | 14x |
| EPS, basic (₹) | 2.88 | 1.13 | +154.9% | 0.21 | 14x |
| Net margin (%) | 10.4 | 5.7 | 2.1 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 643.80 | 532.60 | +20.9% | 562.80 | +14.4% |
| Other income | 62.70 | 38.90 | +61.2% | 64.20 | −2.3% |
| Total income | 706.50 | 571.50 | +23.6% | 627.00 | +12.7% |
| Profit before tax | 35.00 | 21.80 | +60.6% | 603.90 | −94.2% |
| Net profit for the period | 21.20 | 14.00 | +51.4% | 584.00 | −96.4% |
| EPS, basic (₹) | 0.18 | 0.12 | +50.0% | 4.88 | −96.3% |
| Net margin (%) | 3.3 | 2.6 | 103.8 |
Consolidated
- Filed with BSE
- 09 May 2025, 12:14 IST
- Board meeting
- 08 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 May 2025, 12:14 IST
- Board meeting
- 08 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE